Staar Surgical Company (STAA)

$22.11 -0.28 (-1.25%)
Market Cap 1.11B
Revenue (ttm) 239.44M
Net Income (ttm) -80.45M
EPS (ttm) N/A
PE Ratio 34.98
Forward PE 57.41
Profit Margin -33.60%
Debt to Equity Ratio 0.00
Volume 442,900
Avg Vol 907,880
Day's Range N/A - N/A
Shares Out 50.14M
Stochastic %K 6%
Beta 1.26
Analysts Sell
Price Target $28.44

Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, includin...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 626 303 7902
Fax: 626 359 8402
Address:
25510 Commercentre Drive, Lake Forest, United States
stocksmit
stocksmit Aug. 20 at 8:12 PM
$STAA lol. Well. I guess some more again.
0 · Reply
Cpak
Cpak Aug. 20 at 8:09 PM
$STAA bought a starter at 23
0 · Reply
stocksmit
stocksmit Aug. 17 at 7:29 PM
$STAA well. Sold my other wins and loaded up today again. Still think 30 plus is easy in future.
0 · Reply
Arcides
Arcides Aug. 17 at 4:50 PM
$STAA complete piece of shit after a price target lowering....
0 · Reply
Bogwood
Bogwood Aug. 13 at 4:14 AM
$STAA This was a very complex quarter. I really need to update my model once I'm out of the wage cage this week. Cash guide implies double-digit net margins as the floor from here on out, but it's possible it's because one-time expenses (sev & ERP) will shut off in 2H. New "platform" and CTO is so tough to swallow after last year's implosion, but rhetoric around lasik has become so brash. A/R ballooning was the biggest surprise to me, like that shouldn't be happening with consignment, and then there were some credit losses for $800K (!?!).
0 · Reply
scalperD
scalperD Aug. 12 at 10:44 PM
$STAA - 17% short float doing best efforts to keep this down after the better then expected print. Buy here-going higher then the previous Alcon bid of 31.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 12 at 9:27 PM
$STAA Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.16 up 147.06% YoY • Reported revenue of $93.53M up 111.04% YoY
0 · Reply
TradeSun
TradeSun Aug. 12 at 8:21 PM
$STAA https://investors.staar.com/news-and-events/press-releases/2026/08-12-2026-210127260 Very interesting read!
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Aug. 12 at 8:17 PM
$STAA
0 · Reply
Fibonaccino
Fibonaccino Aug. 12 at 8:10 PM
$STAA Staar Surgical Q2 EPS $0.16 Beats $0.15 Estimate, Sales $93.535M Beat $90.589M Estimate
0 · Reply
Latest News on STAA
Staar Surgical price target lowered to $28 from $31 at Stifel

2026-08-17T10:45:06.000Z - 13 days ago

Staar Surgical price target lowered to $28 from $31 at Stifel

Staar Surgical price target lowered to $19 from $20 at UBS

2026-08-17T07:52:45.000Z - 14 days ago

Staar Surgical price target lowered to $19 from $20 at UBS

STAAR Surgical Company Earnings Call Transcript: Q2 2026

Aug 12, 2026, 5:30 PM EDT - 18 days ago

STAAR Surgical Company Earnings Call Transcript: Q2 2026

STAAR Surgical Company Earnings release: Q2 2026

Aug 12, 2026, 5:30 PM EDT - 18 days ago

STAAR Surgical Company Earnings release: Q2 2026

STAAR Surgical Company Quarterly report: Q2 2026

Aug 12, 2026, 5:30 PM EDT - 18 days ago

STAAR Surgical Company Quarterly report: Q2 2026

STAAR Surgical Reports Second Quarter 2026 Results

Aug 12, 2026, 4:01 PM EDT - 18 days ago

STAAR Surgical Reports Second Quarter 2026 Results

Staar Surgical appoints Warren Foust as president, CEO

2026-08-04T20:41:46.000Z - 26 days ago

Staar Surgical appoints Warren Foust as president, CEO

STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer

Aug 4, 2026, 4:05 PM EDT - 26 days ago

STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer

STAAR Surgical to Host Second Quarter 2026 Earnings Results Call and Webcast on August 12, 2026

Aug 4, 2026, 4:01 PM EDT - 26 days ago

STAAR Surgical to Host Second Quarter 2026 Earnings Results Call and Webcast on August 12, 2026

Staar Surgical initiated with a Sell at UBS

2026-07-28T12:06:58.000Z - 4 weeks ago

Staar Surgical initiated with a Sell at UBS

Staar Surgical initiated with a Sell at UBS

2026-07-28T10:46:39.000Z - 4 weeks ago

Staar Surgical initiated with a Sell at UBS

Staar Surgical sees Q2 revenue above $90M, consensus $90.2M

2026-07-16T20:05:55.000Z - 6 weeks ago

Staar Surgical sees Q2 revenue above $90M, consensus $90.2M

STAAR Surgical Announces Preliminary Net Sales for Second Quarter 2026

Jul 16, 2026, 4:01 PM EDT - 6 weeks ago

STAAR Surgical Announces Preliminary Net Sales for Second Quarter 2026

STAAR Surgical Company Transcript: AGM 2026

Jun 18, 2026, 11:30 AM EDT - 2 months ago

STAAR Surgical Company Transcript: AGM 2026

STAAR Surgical Company Transcript: Status update

May 27, 2026, 2:30 PM EDT - 3 months ago

STAAR Surgical Company Transcript: Status update

STAAR Surgical Company Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 26, 2026, 4:30 PM EDT - 3 months ago

STAAR Surgical Company Transcript: Stifel 2026 Virtual Ophthalmology Forum

STAAR Surgical Announces Participation in Upcoming Investor Conferences

May 21, 2026, 4:01 PM EDT - 3 months ago

STAAR Surgical Announces Participation in Upcoming Investor Conferences

Staar Surgical upgraded to Outperform from Neutral at Wedbush

2026-05-14T13:33:17.000Z - 3 months ago

Staar Surgical upgraded to Outperform from Neutral at Wedbush

Staar Surgical price target raised to $32 from $27 at Canaccord

2026-05-14T13:12:37.000Z - 3 months ago

Staar Surgical price target raised to $32 from $27 at Canaccord

Staar Surgical price target raised to $27 from $22 at Mizuho

2026-05-14T12:38:32.000Z - 3 months ago

Staar Surgical price target raised to $27 from $22 at Mizuho

Wedbush upgrades Staar Surgical to Outperform on China rebound

2026-05-14T12:03:20.000Z - 3 months ago

Wedbush upgrades Staar Surgical to Outperform on China rebound

Staar Surgical price target raised to $31 from $18 at Stifel

2026-05-14T11:32:55.000Z - 3 months ago

Staar Surgical price target raised to $31 from $18 at Stifel

Staar Surgical price target raised to $33 from $16 at Piper Sandler

2026-05-14T11:11:23.000Z - 3 months ago

Staar Surgical price target raised to $33 from $16 at Piper Sandler

STAAR Surgical Company Earnings Call Transcript: Q1 2026

May 13, 2026, 5:30 PM EDT - 3 months ago

STAAR Surgical Company Earnings Call Transcript: Q1 2026

STAAR Surgical Company Earnings release: Q1 2026

May 13, 2026, 5:30 PM EDT - 3 months ago

STAAR Surgical Company Earnings release: Q1 2026

STAAR Surgical Company Quarterly report: Q1 2026

May 13, 2026, 5:30 PM EDT - 3 months ago

STAAR Surgical Company Quarterly report: Q1 2026

STAAR Surgical to Host First Quarter 2026 Earnings Results Call and Webcast on May 13, 2026

May 4, 2026, 4:01 PM EDT - 4 months ago

STAAR Surgical to Host First Quarter 2026 Earnings Results Call and Webcast on May 13, 2026

STAAR Surgical Company Proxy statement: Proxy filing

May 4, 2026, 8:00 AM EDT - 4 months ago

STAAR Surgical Company Proxy statement: Proxy filing

STAAR Surgical Company Proxy statement: Proxy filing

May 4, 2026, 8:00 AM EDT - 4 months ago

STAAR Surgical Company Proxy statement: Proxy filing

STAAR Surgical Announces Preliminary Net Sales for First Quarter 2026

Apr 8, 2026, 4:01 PM EDT - 5 months ago

STAAR Surgical Announces Preliminary Net Sales for First Quarter 2026

STAAR Surgical Company Earnings Call Transcript: Q4 2025

Mar 3, 2026, 5:30 PM EST - 6 months ago

STAAR Surgical Company Earnings Call Transcript: Q4 2025

STAAR Surgical Company Earnings release: Q4 2025

Mar 3, 2026, 5:30 PM EST - 6 months ago

STAAR Surgical Company Earnings release: Q4 2025

STAAR Surgical Company Shareholder letter: Q4 2025

Mar 3, 2026, 5:30 PM EST - 6 months ago

STAAR Surgical Company Shareholder letter: Q4 2025

STAAR Surgical Company Annual report: Q4 2025

Mar 3, 2026, 5:30 PM EST - 6 months ago

STAAR Surgical Company Annual report: Q4 2025

STAAR Surgical Issues Shareholder Letter

Mar 3, 2026, 4:02 PM EST - 6 months ago

STAAR Surgical Issues Shareholder Letter

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results

Mar 3, 2026, 4:01 PM EST - 6 months ago

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results

STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction

Feb 25, 2026, 4:01 PM EST - 6 months ago

STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction

STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026

Feb 23, 2026, 4:01 PM EST - 6 months ago

STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026

FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction

Feb 17, 2026, 4:01 PM EST - 6 months ago

FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction

STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs

Feb 2, 2026, 7:00 AM EST - 7 months ago

STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs

STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement

Jan 15, 2026, 8:30 AM EST - 8 months ago

STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement

Alcon Terminates Agreement to Acquire STAAR Surgical

Jan 6, 2026, 8:00 PM EST - 8 months ago

Alcon Terminates Agreement to Acquire STAAR Surgical

ALC

Broadwood Partners Comments on STAAR Surgical Shareholders' Rejection of the Company's Proposed Sale to Alcon

Jan 6, 2026, 9:52 AM EST - 8 months ago

Broadwood Partners Comments on STAAR Surgical Shareholders' Rejection of the Company's Proposed Sale to Alcon

ALC

Staar Surgical to reject Alcon takeover bid after failing to win shareholder backing

Jan 6, 2026, 9:46 AM EST - 8 months ago

Staar Surgical to reject Alcon takeover bid after failing to win shareholder backing

ALC

STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders

Jan 6, 2026, 8:47 AM EST - 8 months ago

STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders

Broadwood Partners Denounces STAAR Surgical's Fourth Delay of the Shareholder Vote on the Company's Proposed Sale to Alcon

Dec 19, 2025, 12:59 PM EST - 9 months ago

Broadwood Partners Denounces STAAR Surgical's Fourth Delay of the Shareholder Vote on the Company's Proposed Sale to Alcon

ALC

Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders

Dec 19, 2025, 11:45 AM EST - 9 months ago

Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders

ALC

STAAR Surgical Company Proxy statement: Proxy Filing

Dec 19, 2025, 7:00 AM EST - 9 months ago

STAAR Surgical Company Proxy statement: Proxy Filing

Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.

Dec 17, 2025, 4:53 PM EST - 9 months ago

Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.

ALC

Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails

Dec 17, 2025, 1:17 PM EST - 9 months ago

Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails

ALC

STAAR Stockholders Have a Choice: Vote FOR Alcon's Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value

Dec 17, 2025, 10:55 AM EST - 9 months ago

STAAR Stockholders Have a Choice: Vote FOR Alcon's Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value

ALC

STAAR Surgical Company Proxy statement: Proxy Filing

Dec 17, 2025, 7:00 AM EST - 9 months ago

STAAR Surgical Company Proxy statement: Proxy Filing

Yunqi Capital Comments on Proxy Advisors' Updated Recommendations, Urges Shareholders to Continue to Back the Company's Standalone Trajectory

Dec 16, 2025, 1:32 PM EST - 9 months ago

Yunqi Capital Comments on Proxy Advisors' Updated Recommendations, Urges Shareholders to Continue to Back the Company's Standalone Trajectory

Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction

Dec 16, 2025, 9:12 AM EST - 9 months ago

Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction

ALC

Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon

Dec 16, 2025, 7:00 AM EST - 9 months ago

Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon

ALC

STAAR Surgical Company Proxy statement: Proxy Filing

Dec 16, 2025, 7:00 AM EST - 9 months ago

STAAR Surgical Company Proxy statement: Proxy Filing

STAAR Surgical Company Proxy statement: Proxy Filing

Dec 16, 2025, 7:00 AM EST - 9 months ago

STAAR Surgical Company Proxy statement: Proxy Filing

Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger

Dec 15, 2025, 6:35 PM EST - 9 months ago

Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger

Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon

Dec 12, 2025, 8:40 AM EST - 9 months ago

Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon

ALC

STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process

Dec 11, 2025, 9:47 AM EST - 9 months ago

STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process

ALC

Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon

Dec 11, 2025, 7:00 AM EST - 9 months ago

Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon

ALC

STAAR Surgical Company Proxy statement: Proxy Filing

Dec 11, 2025, 7:00 AM EST - 9 months ago

STAAR Surgical Company Proxy statement: Proxy Filing

Yunqi Capital Comments on STAAR Surgical's Go-Shop Process and Alcon's Revised Offer

Dec 10, 2025, 7:05 AM EST - 9 months ago

Yunqi Capital Comments on STAAR Surgical's Go-Shop Process and Alcon's Revised Offer

ALC

STAAR Surgical Company Proxy statement: Proxy Filing

Dec 10, 2025, 7:00 AM EST - 9 months ago

STAAR Surgical Company Proxy statement: Proxy Filing

STAAR Surgical Company Proxy statement: Proxy Filing

Dec 10, 2025, 7:00 AM EST - 9 months ago

STAAR Surgical Company Proxy statement: Proxy Filing

Broadwood Partners Responds to Alcon's Increase to Proposed Acquisition Price of STAAR Surgical

Dec 9, 2025, 12:39 PM EST - 9 months ago

Broadwood Partners Responds to Alcon's Increase to Proposed Acquisition Price of STAAR Surgical

ALC

Alcon Announces Amended Merger Agreement with STAAR Surgical

Dec 9, 2025, 8:30 AM EST - 9 months ago

Alcon Announces Amended Merger Agreement with STAAR Surgical

ALC

STAAR Surgical Company Proxy statement: Proxy Filing

Dec 9, 2025, 7:00 AM EST - 9 months ago

STAAR Surgical Company Proxy statement: Proxy Filing

Broadwood Partners Reiterates Opposition to STAAR Surgical's Sale to Alcon Following Conclusion of Performative Go-Shop Process

Dec 8, 2025, 1:28 PM EST - 9 months ago

Broadwood Partners Reiterates Opposition to STAAR Surgical's Sale to Alcon Following Conclusion of Performative Go-Shop Process

ALC

Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon

Dec 8, 2025, 8:16 AM EST - 9 months ago

Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon

ALC

STAAR Surgical Announces Expiration of Go-Shop Period

Dec 8, 2025, 8:00 AM EST - 9 months ago

STAAR Surgical Announces Expiration of Go-Shop Period

ALC

STAAR Surgical Company Proxy statement: Proxy Filing

Dec 8, 2025, 7:00 AM EST - 9 months ago

STAAR Surgical Company Proxy statement: Proxy Filing

Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors

Dec 2, 2025, 4:14 PM EST - 9 months ago

Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors

STAAR Surgical Company Proxy statement: Proxy Filing

Nov 17, 2025, 7:00 AM EST - 10 months ago

STAAR Surgical Company Proxy statement: Proxy Filing

Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

Nov 10, 2025, 8:00 AM EST - 10 months ago

Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

ALC

STAAR Surgical Announces Amendments to Alcon Merger Agreement

Nov 7, 2025, 10:10 AM EST - 10 months ago

STAAR Surgical Announces Amendments to Alcon Merger Agreement

ALC

STAAR Surgical Company Proxy statement: Proxy Filing

Nov 7, 2025, 7:00 AM EST - 10 months ago

STAAR Surgical Company Proxy statement: Proxy Filing

Yunqi Capital Applauds STAAR Surgical's Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated

Nov 6, 2025, 6:21 AM EST - 10 months ago

Yunqi Capital Applauds STAAR Surgical's Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated

STAAR Surgical Reports Third Quarter 2025 Results

Nov 5, 2025, 4:01 PM EST - 10 months ago

STAAR Surgical Reports Third Quarter 2025 Results

STAAR Surgical Company Earnings release: Q3 2025

Nov 5, 2025, 4:00 PM EST - 10 months ago

STAAR Surgical Company Earnings release: Q3 2025

Broadwood Partners Condemns Alcon's Fallacious Attacks on STAAR Surgical and Its Prospects

Nov 4, 2025, 11:52 AM EST - 10 months ago

Broadwood Partners Condemns Alcon's Fallacious Attacks on STAAR Surgical and Its Prospects

ALC

Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon

Oct 31, 2025, 12:00 PM EDT - 10 months ago

Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon

ALC

STAAR Surgical Company Proxy statement: Proxy Filing

Oct 30, 2025, 8:00 AM EDT - 10 months ago

STAAR Surgical Company Proxy statement: Proxy Filing

STAAR Surgical Company Proxy statement: Proxy Filing

Oct 28, 2025, 8:00 AM EDT - 10 months ago

STAAR Surgical Company Proxy statement: Proxy Filing

STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon

Oct 27, 2025, 8:00 AM EDT - 10 months ago

STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon

ALC

STAAR Surgical Company Proxy statement: Proxy Filing

Oct 27, 2025, 8:00 AM EDT - 10 months ago

STAAR Surgical Company Proxy statement: Proxy Filing

Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon

Oct 24, 2025, 6:03 PM EDT - 11 months ago

Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon

ALC

Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction

Oct 24, 2025, 8:00 AM EDT - 11 months ago

Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction

ALC

Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders

Oct 23, 2025, 12:09 PM EDT - 11 months ago

Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders

ALC

STAAR Surgical Company Proxy statement: Proxy Filing

Oct 23, 2025, 8:00 AM EDT - 11 months ago

STAAR Surgical Company Proxy statement: Proxy Filing

Staar Surgical's top investor calls shareholder meeting to remove directors

Oct 22, 2025, 7:44 AM EDT - 11 months ago

Staar Surgical's top investor calls shareholder meeting to remove directors

Broadwood Partners Intends to Call Special Meeting to Remove Several STAAR Surgical Directors

Oct 22, 2025, 6:17 AM EDT - 11 months ago

Broadwood Partners Intends to Call Special Meeting to Remove Several STAAR Surgical Directors

Yunqi Capital Issues Letter to STAAR Surgical's Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction

Oct 20, 2025, 5:32 PM EDT - 11 months ago

Yunqi Capital Issues Letter to STAAR Surgical's Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction

ALC

stocksmit
stocksmit Aug. 20 at 8:12 PM
$STAA lol. Well. I guess some more again.
0 · Reply
Cpak
Cpak Aug. 20 at 8:09 PM
$STAA bought a starter at 23
0 · Reply
stocksmit
stocksmit Aug. 17 at 7:29 PM
$STAA well. Sold my other wins and loaded up today again. Still think 30 plus is easy in future.
0 · Reply
Arcides
Arcides Aug. 17 at 4:50 PM
$STAA complete piece of shit after a price target lowering....
0 · Reply
Bogwood
Bogwood Aug. 13 at 4:14 AM
$STAA This was a very complex quarter. I really need to update my model once I'm out of the wage cage this week. Cash guide implies double-digit net margins as the floor from here on out, but it's possible it's because one-time expenses (sev & ERP) will shut off in 2H. New "platform" and CTO is so tough to swallow after last year's implosion, but rhetoric around lasik has become so brash. A/R ballooning was the biggest surprise to me, like that shouldn't be happening with consignment, and then there were some credit losses for $800K (!?!).
0 · Reply
scalperD
scalperD Aug. 12 at 10:44 PM
$STAA - 17% short float doing best efforts to keep this down after the better then expected print. Buy here-going higher then the previous Alcon bid of 31.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 12 at 9:27 PM
$STAA Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.16 up 147.06% YoY • Reported revenue of $93.53M up 111.04% YoY
0 · Reply
TradeSun
TradeSun Aug. 12 at 8:21 PM
$STAA https://investors.staar.com/news-and-events/press-releases/2026/08-12-2026-210127260 Very interesting read!
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Aug. 12 at 8:17 PM
$STAA
0 · Reply
Fibonaccino
Fibonaccino Aug. 12 at 8:10 PM
$STAA Staar Surgical Q2 EPS $0.16 Beats $0.15 Estimate, Sales $93.535M Beat $90.589M Estimate
0 · Reply
Synaptric
Synaptric Aug. 12 at 7:39 PM
Three names are reading Extremely Bullish going into earnings this afternoon. $CSCO was in the Bearish zone the first half of the period but has steadily climbed since. $RNXT began Extremely Bullish, then dipped into Neutral, but has since climbed to highest position of this group. $COHR has been Bullish or Extremely Bullish the entire time. On the other end $STAA spent several days in this Bullish zone but fell hard three days ago to end the most bearish of the bunch. Note all of these are sloped upward today except $INO which has ranged all over the place this period.
0 · Reply
Bogwood
Bogwood Aug. 12 at 3:02 PM
$STAA Finger on the trigger to see how much progress they've made with their bottom line. I could see a world where they reinstate guidance as long as the ERP is in it's final stages.
0 · Reply
Estimize
Estimize Aug. 12 at 3:01 PM
$STAA reports after the close, Estimize Consensus +0.06 EPS and +6.47M Revs compared to WS http://www.estimize.com/staa/fq2-2026?utm_conten
0 · Reply
ETAlpha
ETAlpha Aug. 10 at 3:12 PM
$STAA rejects cheap buyout as operational turnaround takes off! Ophthalmic medical leader $STAA (STAAR Surgical) gains +3.68% to $25.10 today, dynamically absorbing localized friction above horizontal demand. Textbook long-term value creation! Broadwood’s 30-year conviction rejected Alcon’s lowball $30.75 offer Q1 revenue acceleration and Point72’s 5.2% stake fully validate the structural thesis. accumulating starter positions on pullbacks near the $23.50-$24.50 baseline demand shelf with tight stops, holding for high-velocity expansion! Visit our homepage for exclusive real-time alpha and stock breakdowns!
0 · Reply
Estimize
Estimize Aug. 6 at 8:00 PM
Wall St is expecting 0.15 EPS for $STAA Q3 [Reporting 11/04 AMC] http://www.estimize.com/intro/staa?chart=historical&metric_name=eps&utm_co
0 · Reply
StockBraker
StockBraker Aug. 6 at 1:03 PM
$STAA Time to start looking at selling some covered calls in the $40+ range, Sept 18 expiration.
0 · Reply
fireanalyst
fireanalyst Aug. 6 at 3:24 AM
$STAA exited position after carefully reviewing the pre announcement. Buried in the release was the disclosure of erp system issues. Add that with the selloff since then and I think they gonna miss on eps
0 · Reply
scalperD
scalperD Aug. 3 at 1:26 PM
$STAA - Short interest dropped from 17 to 10 today. Believe the worst is in the name.
0 · Reply
stocksmit
stocksmit Jul. 30 at 11:53 PM
$STAA
0 · Reply
scalperD
scalperD Jul. 28 at 3:03 PM
$STAA - UBS initiated with a sell. The analyst,Patrick Wood has a 54% success rate on Tip Ranks with an avg return of .80% since 2017. That's incredibly poor. Ranked 7619 out of 10,081 analysts Buy STAA on this weakness
0 · Reply
stocksmit
stocksmit Jul. 28 at 1:46 PM
$STAA hmmm. Fire sale I think. I bought more. Shares shorted dropped quite a bit it appears. $30
0 · Reply
KernelKeltner
KernelKeltner Jul. 17 at 3:59 PM
$STAA slipped 5.6% pre-market after preliminary Q2 revenue came in around $90M, slightly below the $90.25M consensus. The headline miss looks small, while the underlying regional picture was mixed. China, Asia-Pacific, and the Americas continued to show strength with double-digit growth, but EMEA was pressured by ongoing Middle East uncertainty. The market reaction shows investors are watching more than just revenue numbers. The focus will be on growth durability, regional recovery, and whether core markets can keep offsetting weaker areas.
1 · Reply